GALNT16: A Potential Drug Target and Biomarker (G57452)

Target Name: GALNT16

NCBI ID: G57452

GALNT16

Other Name(s): polypeptide N-acetylgalactosaminyltransferase 16 | Polypeptide N-acetylgalactosaminyltransferase 16 | GLT16_HUMAN | Protein-UDP acetylgalactosaminyltransferase-like protein 1 | UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-like protein 1 | Polypeptide GalNAc transferase-like protein 1 | GALNACT16 | Pp-GaNTase-like protein 1 | galNAc-T-like protein 1 | Polypeptide N-acetylgalactosaminyltransferase-like protein 1 | Polypeptide GalNAc transferase 16 | Polypeptide N-acetylgalactosaminyltransferase-like 1 | GALNT16 variant 1 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 1 | polypeptide GalNAc transferase 16 | KIAA1130 | GALNTL1 | putative polypeptide N-acetylgalactosaminyltransferase-like protein 1 | GalNAc-T-like protein 1 | pp-GaNTase-like protein 1 | polypeptide N-acetylgalactosaminyltransferase-like protein 1 | polypeptide GalNAc transferase-like protein 1 | GalNAc-T16 | protein-UDP acetylgalactosaminyltransferase-like protein 1 | Polypeptide N-acetylgalactosaminyltransferase 16, transcript variant 1 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 16

GALNT16: A Potential Drug Target and Biomarker

GALNT16 is a gene that encodes a protein known as N-acetylgalactosaminyltransferase 16 (NAGLT16). This protein plays a crucial role in the metabolism of lactose, which is a sugar found in milk and other dairy products. NAGLT16 is responsible for converting lactose to its key component, N-acetylgalactosaminyl, which is then used by the body to absorb and utilize the sugar.

GALNT16 is a member of the GALNT family of enzymes, which are involved in the transfer of different amino acids to specific carbohydrates. The GALNT family is known for its role in the development and maintenance of the nervous system, as well as the regulation of various cellular processes.

GALNT16 has been identified as a potential drug target due to its involvement in the metabolism of lactose. Many diseases, including diabetes, are caused by the body's inability to properly absorb and utilize glucose, which is the primary source of energy for the body. GALNT16 plays a key role in this process, as it is involved in the conversion of lactose to N-acetylgalactosaminyl, which is then used to absorb and utilize glucose.

In addition to its role in glucose metabolism, GALNT16 is also involved in the regulation of various cellular processes, including cell signaling, DNA replication, and cell division. It has been shown to play a key role in the development and maintenance of cancer cells, as well as the regulation of inflammation and stress responses.

GALNT16 has also been identified as a potential biomarker for several diseases, including cancer, diabetes, and neurodegenerative diseases. The ability to diagnose and monitor these diseases using GALNT16 as a biomarker could have a significant impact on patient outcomes.

In conclusion, GALNT16 is a gene that has the potential to be a drug target and biomarker. Its involvement in the metabolism of lactose and its involvement in various cellular processes make it an attractive target for research and development of new treatments for a variety of diseases. Further research is needed to fully understand the role of GALNT16 in disease and to develop effective treatments.

Protein Name: Polypeptide N-acetylgalactosaminyltransferase 16

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor

The "GALNT16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets